Dyadic International Inc當前公司基本面數據相對健康,增長潛力較大。當前估值合理,在生物技術與醫療研究行業排名141/404位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價5.00。中期看,股價處於下降通道。近一個月,市場表現較強,技術面和基本面綜合得分較高,較強的走勢獲得基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。
Dyadic International Inc評分
相關信息
行業排名
141 / 404
全市場排名
264 / 4582
所屬行業
生物技術與醫療研究
壓力支撐
由於公司未披露,未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
1
分析師
買入
評級
5.000
目標均價
+405.05%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議
Dyadic International Inc亮點
亮點風險
Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica, which the Company named C1. The Compny’s lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.
Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica, which the Company named C1. The Compny’s lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.
公司代碼DYAI
公司Dyadic International Inc
CEOEmalfarb (Mark A)
網址https://dyadic.com/
常見問題
Dyadic International Inc(DYAI)的當前股價是多少?
Dyadic International Inc(DYAI)的當前股價是 1.000。
Dyadic International Inc 的股票代碼是什麼?
Dyadic International Inc的股票代碼是DYAI。
Dyadic International Inc股票的52週最高點是多少?
Dyadic International Inc股票的52週最高點是2.143。
Dyadic International Inc股票的52週最低點是多少?
Dyadic International Inc股票的52週最低點是0.711。
Dyadic International Inc的市值是多少?
Dyadic International Inc的市值是36.18M。
Dyadic International Inc的淨利潤是多少?
Dyadic International Inc的淨利潤為-5.81M。
現在Dyadic International Inc(DYAI)的股票是買入、持有還是賣出?
根據分析師評級,Dyadic International Inc(DYAI)的總體評級為買入,目標價格為5.000。
Dyadic International Inc(DYAI)股票的每股收益(EPS TTM)是多少
Dyadic International Inc(DYAI)股票的每股收益(EPS TTM)是-0.220。